Results 261 to 270 of about 19,887 (300)

Interferon free therapy with direct acting antivirals for HCV

Liver International, 2013
AbstractThe current treatment for hepatitis C virus (HCV) genotype 1 chronic infection is the addition of direct‐acting antivirals (DAA) with a protease inhibitor (telaprevir or boceprevir) to the pegylated interferon (PEG‐IFN) plus ribavirin (RBV) regimen.
Tarik, Asselah, Patrick, Marcellin
openaire   +2 more sources

Direct acting antivirals failure: cause and retreatment options

Expert Review of Gastroenterology & Hepatology, 2018
Chronic hepatitis C (HCV) infection is a systemic life-threatening condition that can lead to hepatic and extra-hepatic complications. Sustained virological response (SVR) is associated with a regression of most liver and non-liver manifestations, which reduce mortality.
Lucia, Parlati, Stanislas, Pol
openaire   +2 more sources

Extrahepatic manifestations of HCV: the role of direct acting antivirals

Expert Review of Anti-infective Therapy, 2017
Hepatitis C virus (HCV) represents a major health concern, as nearly 3 million people become newly infected by this pathogen annually. The majority of infected individuals fail to clear the virus, and chronicity is established. Chronic HCV patients are at high risk for liver disease, ranging from mild fibrosis to cirrhosis and severe hepatocellular ...
María Laura, Polo, Natalia, Laufer
openaire   +2 more sources

Role of Liver Biopsy in the Era of Direct-Acting Antivirals

Current Gastroenterology Reports, 2013
An accurate assessment of the degree of fibrosis or presence of cirrhosis is critical both for the appropriate management of, and to provide prognosis for, patients with chronic hepatitis C infection. In the new era of direct acting antivirals, large numbers of patients may enter therapy, and although liver biopsy remains the gold standard, it is not ...
Humberto C, Gonzalez, Syed Mohammed, Jafri, Stuart C, Gordon   +2 more
openaire   +2 more sources

[Direct-acting antiviral-resistant variant].

Nihon rinsho. Japanese journal of clinical medicine, 2015
Recently, IFN-free NS5A inhibitor daclatasvir and protease inhibitor asunaprevir combination treatment was approved for genotype 1b HCV-infected patients who were ineligible or who failed to respond to previous therapies. NS5A inhibitor-resistant variants occasionally exist in HCV-infected patients who have never been exposed to direct-acting ...
Michio, Imamura, Kazuaki, Chayama
openaire   +1 more source

IL28B in the Era of Direct-acting Antivirals for Hepatitis C

Journal of Clinical Gastroenterology, 2013
The IL28B genotype is the strongest baseline predictor of hepatitis C treatment response with peginterferon-α and ribavirin. In 2011, 2 protease inhibitors were approved for genotype 1 infection in combination with peginterferon-α and ribavirin, and boceprevir and telaprevir attenuate the association between the IL28B genotype and treatment response ...
openaire   +2 more sources

Direct-acting antivirals for paediatric HCV: we got there

Nature Reviews Gastroenterology & Hepatology, 2017
In a new report, adolescents with genotype 2 or 3 HCV infection who were given sofosbuvir and ribavirin showed a near 100% sustained virologic response. This study is the beginning of a new wave of treatments for paediatric HCV infection, forming part of a global strategy to eradicate viral hepatitis.
openaire   +2 more sources

Direct acting antiviral therapy after liver transplantation

Current Opinion in Gastroenterology, 2016
Historically, postliver transplant patients with chronic hepatitis C have had worse outcomes than nonhepatitis C-related causes because of accelerated fibrosis posttransplantation and the lack of effective well tolerated therapies for hepatitis C, and posttransplant hepatitis C patients have been considered a special population.
openaire   +2 more sources

Direct-acting antiviral treatment for HCV

The Lancet Infectious Diseases, 2016
Stelliana, Goutzamanis, Joseph, Doyle, Alexander, Thompson, Margaret, Hellard, Peter, Higgs   +4 more
openaire   +2 more sources

Direct-Acting Antiviral Agents

Clinics in Liver Disease, 2015
Tatyana Kushner, Vandana Khungar
openaire   +1 more source